INDEPENDENT THINKING. WHOLE-FOOD LIVING.NO ANIMALS / NO OIL
THENANODIET
← THE EVIDENCE INDEX

The Study Library.

8,456 peer-reviewed studies, each with a short note written from its published abstract: what kind of study it was, who took part, what was measured and what the authors reported. Observational studies show associations, not proof.

People assigned to a diet, food or program and measured.

256 studies · page 9 of 11

2010 / Randomized controlled trial

B vitamins slowed brain atrophy rates in older adults with mild cognitive impairment

In a randomized trial, 168 older adults with mild cognitive impairment received daily B vitamins (0.8 mg folic acid, 0.5 mg B12, 20 mg B6) or placebo for 24 months. Brain atrophy averaged 0.76% per year in the active group versus 1.08% with placebo (P = 0.001). The response was greater among individuals with baseline homocysteine above 13 micromol/L, whose atrophy rate dropped by 53% (P = 0.001). Faster atrophy was linked to lower cognitive test scores.

Smith AD, Smith SM, de Jager CA, et al. PLoS One, 2010. PMID 20838622

2009 / Interventional trial

Treatment with rebamipide, alpha-lipoic acid, and vitamin C significantly improved hearing levels across all frequencies in elderly patients with hearing loss.

To assess the efficacy of radical scavengers for age-related hearing loss, 46 elderly patients were given oral rebamipide (300 mg/day), alpha-lipoic acid (60 mg/day), and vitamin C (600 mg/day) for at least 8 weeks. Following treatment, hearing levels were significantly improved at all frequencies.

Takumida M, Anniko M Acta Otolaryngol, 2009. PMID 18607930

2009 / Double-blind, parallel-group, placebo-controlled randomized trial

Yamabushitake (Hericium erinaceus) supplementation significantly improved cognitive function scores in adults with mild cognitive impairment.

Thirty Japanese men and women aged 50 to 80 with mild cognitive impairment were randomized to take either Yamabushitake (four 250 mg tablets containing 96% dry powder three times daily) or placebo for 16 weeks, followed by 4 weeks of observation. At weeks 8, 12, and 16, the Yamabushitake group showed significantly increased cognitive function scale scores compared with placebo, with scores increasing with duration of intake. However, scores decreased significantly by 4 weeks after terminating intake. Laboratory tests showed no adverse effects.

Mori K, Inatomi S, Ouchi K, et al. Phytother Res, 2009. PMID 18844328

2009 / Randomized controlled trial (subgroup analysis)

In male smokers with high dietary vitamin C, vitamin E increased mortality at ages 50-62 but decreased it at ages 66-69.

Researchers analyzed data from 29,133 Finnish male smokers in the ATBC Study over a median follow-up of 6.1 years (3,571 deaths) to examine if age, smoking, and dietary vitamin C modified the effect of 50 mg/day vitamin E on mortality. Age and dietary vitamin C intake had a second-order interaction with vitamin E supplementation. Among participants with dietary vitamin C intake above the median (90 mg/day), vitamin E increased mortality in those aged 50-62 years by 19% (95% CI: 5, 35) but decreased mortality in those aged 66-69 years by 41% (95% CI: -56, -21). Vitamin E had no effect among participants with vitamin C intake below the median, and smoking quantity did not modify the effect.

Hemilä H, Kaprio J Am J Epidemiol, 2009. PMID 19218294

2009 / Double-blind randomized placebo-controlled trial

High-dose isoflavones improved quality-of-life subscales in post-menopausal women without significantly altering cognition.

A 12-week randomized trial evaluated 93 post-menopausal women receiving either 20 g soy protein with 160 mg total isoflavones or a taste-matched whole milk protein placebo. Eighty-four women completed the study. Women taking isoflavones experienced significant improvements in all four Menopause-specific Quality of Life subscales (vasomotor, psychosexual, physical, and sexual), with no changes in the placebo group. No significant changes occurred within groups for cognition, serum androgens, or plasma lipids, though a group-by-time interaction showed significantly lower total testosterone and HDL levels in the isoflavone group versus placebo at study end.

Basaria S, Wisniewski A, Dupree K, et al. J Endocrinol Invest, 2009. PMID 19411814

2009 / Randomized controlled trial (substudy)

Supplementation with vitamin E, beta carotene, or vitamin C did not slow cognitive change over 5.4 years in older women with or at risk for cardiovascular disease.

In a substudy of the Women's Antioxidant Cardiovascular Study, 2,824 women aged >=65 years were tested 4 times over 5.4 years to evaluate the effects of vitamin E (402 mg alternate days), beta carotene (50 mg alternate days), and vitamin C (500 mg daily). Vitamin E and beta carotene were not associated with slower rates of cognitive change compared to placebo (mean difference in change: -0.01, 95% CI -0.05 to 0.04, P=0.78 for vitamin E; 0.03, 95% CI -0.02 to 0.07, P=0.28 for beta carotene). Vitamin C was associated with better performance at the final assessment (mean difference 0.13, 95% CI 0.06 to 0.20, P=0.0005) but was not associated with cognitive change over time (mean difference 0.02, 95% CI -0.03 to 0.07, P=0.39).

Kang JH, Cook NR, Manson JE, et al. Circulation, 2009. PMID 19451353

2009 / Randomized controlled trial

Vitamin E maintained cognition in Alzheimer's patients who showed reduced oxidative stress, but was linked to worse cognitive decline in non-respondents.

Fifty-seven Alzheimer's disease patients were randomized to receive placebo or 800 IU of vitamin E daily for six months, with 33 finishing the trial. Among vitamin E-treated patients, respondents showed lower blood oxidized glutathione (GSSG) levels and maintained cognitive test scores. In non-respondents where oxidative stress was not prevented, cognition decreased sharply to levels lower than those taking placebo.

Lloret A, Badía MC, Mora NJ, et al. J Alzheimers Dis, 2009. PMID 19494439

2009 / Prospective pre-post pilot study

A 6-month treatment with concentrated soy extract rich in isoflavones improved skin thickness, collagen, and elastic fibers in postmenopausal women.

A prospective pilot study examined 30 postmenopausal women treated with 100 mg/day of an isoflavone-rich concentrated soy extract for 6 months, assessing gluteal skin punches before and after. Isoflavone treatment produced a 9.46% increase in epidermal thickness in 23 patients and reduced the papillary index (indicating reduced wrinkling) in 21 women. Dermal collagen increased in 25 women (86.2%), elastic fibers increased in 22 women (75.8%), and dermal blood vessels significantly increased in 21 women.

Accorsi-Neto A, Haidar M, Simões R, et al. Clinics (Sao Paulo), 2009. PMID 19578653

2009 / Randomized, double-blind, placebo-controlled trial

Oral ketogenic agent AC-1202 elevated serum ketones and improved ADAS-Cog scores compared with placebo in patients with mild to moderate Alzheimer's disease.

A 90-day randomized, double-blind, placebo-controlled trial evaluated daily administration of the ketogenic compound AC-1202 in 152 patients with mild to moderate Alzheimer's disease who maintained a normal diet. AC-1202 significantly elevated serum beta-hydroxybutyrate 2 hours post-dose. Compared to placebo, AC-1202 led to a significant difference in mean change from baseline in ADAS-Cog score at Day 45 across the ITT (1.9-point difference, p = 0.0235), per-protocol (2.53-point difference, p = 0.0324), and dosage-compliant (2.6-point difference, p = 0.0215) groups. Improvements were most pronounced in APOE4-negative subjects, showing significant ADAS-Cog differences at both Day 45 and Day 90. Adverse events were more frequent with AC-1202, primarily mild-to-moderate and transient gastrointestinal issues.

Henderson ST, Vogel JL, Barr LJ, et al. Nutr Metab (Lond), 2009. PMID 19664276

2009 / Double-blind randomized parallel trial

Chronic American ginseng supplementation induced oxidative stress and altered antioxidant markers in postmenopausal women.

In a double-blind parallel study, 12 postmenopausal women took 1,000 mg of American ginseng powder daily for 4 months, while 13 took a placebo, with treadmill walking tests conducted before and after supplementation. Ginseng had no effect on heart rate, blood pressure, plasma glucose, or lactate at rest or post-exercise. However, the ginseng group showed higher resting plasma glutathione disulfide (GSSG), a lower GSH:GSSG ratio, lower resting total antioxidant content, and elevated plasma malondialdehyde and urine 8-hydroxydeoxyguanosine. Erythrocyte superoxide dismutase and GSH reductase activities were also increased following ginseng supplementation.

Dickman JR, Koenig RT, Ji LL J Am Coll Nutr, 2009. PMID 19828907

2009 / Randomized controlled trial

Lycium barbarum juice enhanced specific immune markers and subjective well-being in older adults.

In a 30-day trial of 60 healthy adults aged 55 to 72, participants consumed 120 mL daily of standardized Lycium barbarum juice or placebo. The juice group experienced significant increases in lymphocytes, interleukin-2, and immunoglobulin G relative to baseline and placebo. Subjective ratings of general well-being also improved, whereas no changes occurred in natural killer cells, CD4, CD8, or clinical safety markers.

Amagase H, Sun B, Nance DM J Med Food, 2009. PMID 19857084

2008 / Double-blind, randomized, controlled clinical trial

Daily DHEA supplementation for one year showed no benefit on cognitive performance or quality of life in healthy older adults.

A double-blind trial evaluated the effects of 50 mg daily oral DHEA versus placebo for 1 year in 225 healthy older adults. There were no differences between the DHEA and placebo groups in change over time in cognitive function (P > .10). Over time, BDI scores decreased for men (P = .006) and women (P = .02), and Satisfaction with Life Scale scores increased for women (P = .004), but no differences were observed between the DHEA and placebo groups on these measures, the SF-36, the Life Satisfaction Index-Z scale, or sexual function scales (P > .10).

Kritz-Silverstein D, von Mühlen D, Laughlin GA, et al. J Am Geriatr Soc, 2008. PMID 18482290

2008 / Randomized, double-blind, placebo-controlled crossover trial

Maca supplementation reduced psychological symptoms and sexual dysfunction in postmenopausal women without altering hormone levels.

Fourteen postmenopausal women completed a randomized, double-blind, placebo-controlled crossover trial receiving 3.5 g/day of powdered Maca and matching placebo for 6 weeks each. No significant differences were observed in serum concentrations of estradiol, FSH, LH, or SHBG between baseline, Maca, and placebo (P > 0.05). However, Maca significantly reduced Greene Climacteric Scale scores for psychological symptoms, including anxiety, depression, and sexual dysfunction compared to baseline and placebo (P < 0.05). Yeast-based assays showed no physiologically significant estrogenic or androgenic activity in Maca extracts.

Brooks NA, Wilcox G, Walker KZ, et al. Menopause, 2008. PMID 18784609

2008 / Pilot clinical trial

Comprehensive lifestyle changes were associated with higher peripheral blood mononuclear cell telomerase activity.

A pilot study evaluated 30 men with low-risk prostate cancer asked to adopt comprehensive lifestyle modifications for 3 months. In 24 participants with adequate samples, natural log-transformed telomerase activity was 2.00 at baseline and 2.22 after 3 months (p = 0.031). Increased telomerase activity correlated with lower LDL cholesterol (r = -0.36, p = 0.041) and less psychological distress (r = -0.35, p = 0.047).

Ornish D, Lin J, Daubenmier J, et al. Lancet Oncol, 2008. PMID 18799354

2008 / Comparative clinical trial

Protein restriction, but not severe calorie restriction, decreased circulating IGF-1 in humans.

Researchers analyzed circulating markers from long-term human studies lasting 1 and 6 years. Severe calorie restriction with adequate nutrition did not change serum IGF-1 or the IGF-1 to IGFBP-3 ratio. In contrast, lowering protein intake from 1.67 to 0.95 g/kg/day for 3 weeks in six calorie-restricted volunteers reduced serum IGF-1 from 194 to 152 ng/mL.

Fontana L, Weiss EP, Villareal DT, et al. Aging Cell, 2008. PMID 18843793

2008 / Repeated-measures controlled dietary intervention

Dietary protein requirements based on nitrogen balance did not differ between healthy younger and older adults.

Twenty-three younger and 19 older adults completed three 18-day dietary trials with protein intakes of 0.50, 0.75, and 1.00 g/kg/d. Nitrogen balance was evaluated from days 14 to 17 of each trial to determine individual protein requirements using linear regression. The mean (+/- SD) protein requirement was not different between younger and older subjects (0.61 +/- 0.14 vs. 0.58 +/- 0.12 g/kg/d, respectively). An adequate protein allowance for combined subjects was calculated to be 0.85 +/- 0.21 g/kg/d, which did not differ statistically from the Recommended Dietary Allowance (RDA).

Campbell WW, Johnson CA, McCabe GP, et al. Am J Clin Nutr, 2008. PMID 18996869

2008 / Randomized, placebo-controlled split-face trial

A topical cosmetic containing 4% niacinamide significantly reduced eye-area wrinkles and skin roughness compared with control over 8 weeks.

A randomized, placebo-controlled, split-face study evaluated the anti-wrinkle effects of a cosmetic containing 4% niacinamide versus a control cosmetic applied for 8 weeks in 30 healthy Japanese females with eye-area wrinkles. The 4% niacinamide cosmetic demonstrated marked and moderate improvement in 64% of subjects, showing a significant difference compared to the control site (P < 0.001). Wrinkle grades decreased significantly more than baseline (P < 0.001) and control (P < 0.001), and skin roughness (Ra value) reductions were also significantly greater than baseline (P < 0.01) and control (P < 0.05). One subject discontinued due to minimal irritation.

Kawada A, Konishi N, Oiso N, et al. J Dermatol, 2008. PMID 19017042

2008 / Randomized, double-blind, placebo-controlled clinical trial

Ginkgo biloba extract did not reduce the incidence of all-cause dementia or Alzheimer disease in elderly individuals.

A randomized, double-blind, placebo-controlled trial evaluated whether 120 mg of Ginkgo biloba extract twice daily reduced incident dementia compared to placebo over a median follow-up of 6.1 years. Overall, 523 participants developed dementia (277 in the G. biloba group and 246 in the placebo group). The hazard ratio for G. biloba compared with placebo was 1.12 (95% CI, 0.94-1.33; P = .21) for all-cause dementia and 1.16 (95% CI, 0.97-1.39; P = .11) for Alzheimer disease. G. biloba also did not alter progression to dementia in participants with mild cognitive impairment (HR, 1.13; 95% CI, 0.85-1.50; P = .39).

DeKosky ST, Williamson JD, Fitzpatrick AL, et al. JAMA, 2008. PMID 19017911

2008 / Clinical trial and in vitro study

Application of a 1% CoQ10 cream for five months reduced dermatologist-observed wrinkle score grade.

Researchers examined the mechanisms of coenzyme Q10 (CoQ10) on UVB-induced wrinkle formation in vitro and in a clinical trial. In vitro, CoQ10 decreased UVB-induced IL-6 production in normal human keratinocytes and significantly decreased MMP-1 production in fibroblasts over 24 hours. In the clinical trial, the use of a 1% CoQ10 cream for five months reduced wrinkle score grade as observed by a dermatologist.

Inui M, Ooe M, Fujii K, et al. Biofactors, 2008. PMID 19096121

2007 / Randomized controlled trial

A multi-component exercise regimen improved physical functioning and reduced tibial shaft weakening in elderly women.

In a 1-year randomized controlled trial, 149 healthy women aged 70-78 were assigned to resistance training (RES), balance-jumping training (BAL), a combination (COMB), or control (CON). Self-rated physical functioning showed a mean inter-group difference of 10% (95% CI: 0-22%) favoring COMB versus CON. Leg extensor force increased more in RES (14%; 4-25%) and COMB (13%; 3-25%) compared with CON, while dynamic balance improved in BAL (6%; 1-11%) and COMB (8%; 3-12%). There were no inter-group differences in BMC at the proximal femur, but in COMB women training at least twice a week, tibial shaft structure weakened 2% (0-4%) less than in the CON group.

Karinkanta S, Heinonen A, Sievänen H, et al. Osteoporos Int, 2007. PMID 17103296

2007 / Cross-sectional comparison and pre-post exercise intervention

A 3-month aerobic exercise intervention increased EPC colony-forming units and migratory activity in sedentary middle-aged and older men.

Researchers assessed EPC clonogenic and migratory capacity in 46 healthy sedentary men across three age groups, and in 10 sedentary middle-aged and older men before and after a 3-month aerobic exercise intervention. EPC colony-forming units were approximately 75% lower in middle-aged (12 +/- 3) and older (8 +/- 2) men compared with young men (40 +/- 7, P < 0.01), while migration was reduced in older (453 +/- 72) versus young (813 +/- 114) and middle-aged (760 +/- 114) men. In the intervention group, 3 months of aerobic exercise significantly increased EPC colony-forming units from 10 +/- 3 to 22 +/- 5 and migratory activity from 683 +/- 96 to 1,022 +/- 123 (P < 0.05).

Hoetzer GL, Van Guilder GP, Irmiger HM, et al. J Appl Physiol (1985), 2007. PMID 17158243

2007 / Double-blind randomized placebo-controlled trial

Folic acid supplementation (800 µg/day for 3 years) slowed age-related low-frequency hearing decline in older Dutch adults.

A double-blind trial in the Netherlands randomized 728 older adults with elevated homocysteine to daily oral folic acid (800 microg) or placebo for 3 years. After 3 years, low-frequency hearing thresholds increased by 1.0 dB (95% CI, 0.6 to 1.4 dB) in the folic acid group versus 1.7 dB (CI, 1.3 to 2.1 dB) in the placebo group (difference, -0.7 dB [CI, -1.2 to -0.1 dB]; P = 0.020). Folic acid supplementation did not affect the decline in high-frequency hearing. Limitations include strict homocysteine eligibility criteria and the study taking place in a setting without food folic acid fortification, where baseline folate levels were about half those of the U.S. population.

Durga J, Verhoef P, Anteunis LJ, et al. Ann Intern Med, 2007. PMID 17200216

2007 / Randomized crossover trial

Substituting soy nuts into a Therapeutic Lifestyle Changes diet significantly decreased hot flashes and improved menopausal symptoms in postmenopausal women.

Sixty healthy postmenopausal women were randomized in a crossover design to an 8-week Therapeutic Lifestyle Changes (TLC) diet alone or a TLC diet where one-half cup of soy nuts (providing 25 g soy protein and 101 mg aglycone isoflavones) replaced 25 g of nonsoy protein. Compared to TLC alone, the TLC diet plus soy nuts was associated with a 45% decrease in hot flashes in women with >4.5 hot flashes/day at baseline (7.5 +/- 3.6 vs. 4.1 +/- 2.6/day, p < 0.001) and a 41% decrease in those with <=4.5/day (2.2 +/- 1.2 vs. 1.3 +/- 1.1, p < 0.001). Soy nut intake also significantly improved quality-of-life scores, with decreases in vasomotor (19%, p = 0.004), psychosocial (12.9%, p = 0.01), and physical scores (9.7%, p = 0.045), and a 17.7% reduction in sexual symptoms (p = 0.129). Exercise amount had no effect on hot flash reduction.

Welty FK, Lee KS, Lew NS, et al. J Womens Health (Larchmt), 2007. PMID 17439381

2007 / Double-blind, placebo-controlled randomized trial

Combined oral and topical lutein and zeaxanthin provided the highest antioxidant protection in human skin following UV irradiation.

A double-blind, placebo-controlled clinical trial evaluated the effects of lutein and zeaxanthin administered orally, topically, or via combined oral and topical routes on five skin physiology parameters in human subjects. Combined oral and topical administration offered the highest degree of antioxidant protection, though individual oral and topical administration also showed significant activity in the skin. Furthermore, oral lutein administration appeared to provide better protection than topical application when evaluating changes in lipid peroxidation and photoprotective activity after UV irradiation.

Palombo P, Fabrizi G, Ruocco V, et al. Skin Pharmacol Physiol, 2007. PMID 17446716